NCT04158739

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2020-01-22Est. Completion: 2022-09-30

Enrollment target: 16 participants

Locations

Children's Hospital of Alabama, Birmingham, Alabama, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
Children's Hospital of Orange County, Orange, California, United States
UCSF Medical Center-Mission Bay, San Francisco, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Children's National Medical Center, Washington D.C., District of Columbia, United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
Riley Hospital for Children, Indianapolis, Indiana, United States
C S Mott Children's Hospital, Ann Arbor, Michigan, United States
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Washington University School of Medicine, St Louis, Missouri, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Acute Myeloid LeukemiaRelapse/Recurrence

This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reindu…

Brno, CzechiaEst. completion Jan 2028

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

This phase I/II trial studies the best dose of sorafenib when given together with busulfan and fludarabine in treating p…

Houston, United StatesEst. completion Dec 31, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.